Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and α-glycosidase inhibitors

  • Bioorg Chem. 2019 Apr:85:191-197. doi: 10.1016/j.bioorg.2018.12.035.
Serdar Burmaoglu  1 Ali Osman Yilmaz  2 M Fatih Polat  3 Rüya Kaya  4 İlhami Gulcin  2 Oztekin Algul  5
Affiliations
  • 1. Tercan Vocational High School, Erzincan Binali Yildirim University, Erzincan 24800, Turkey; Department of Chemistry, Faculty of Science, Atatürk University, Erzurum 25240, Turkey. Electronic address: [email protected].
  • 2. Department of Chemistry, Faculty of Science, Atatürk University, Erzurum 25240, Turkey.
  • 3. Department of Pharmaceutical Basic Sciences, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan 24100, Turkey.
  • 4. Central Research and Application Laboratory, Agri Ibrahim Cecen University, Agri 04100, Turkey.
  • 5. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Mersin University, Mersin 33169, Turkey. Electronic address: [email protected].
Abstract

A novel class of fluoro-substituted tris-chalcones derivatives (5a-5i) was synthesized from phloroglucinol and corresponding benzaldehydes. A three step synthesis method was followed for the production of these tris-chalcone compounds. The structures of the newly synthesized compounds (5a-5i) were confirmed on the basis of IR, 1H NMR, 13C NMR, and elemental analysis.The compounds' inhibitory activities were tested against human Carbonic Anhydrase I and II isoenzymes (hCA I and hCA II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase (α-Gly). These chalcone derivatives had Ki values in the range of 19.58-78.73 nM for hCA I, 12.23-41.70 nM for hCA II, 1.09-6.84 nM for AChE, 8.30-32.30 nM for BChE and 0.93 ± 0.20-18.53 ± 5.06 nM against α-glycosidase. These results strongly support the promising nature of the tris-chalcone scaffold as selective Carbonic Anhydrase, acetylcholinesterase, butyrylcholinesterase, and α-glycosidase inhibitor. Overall, due to these derivatives' inhibitory potential on the tested Enzymes, they are promising drug candidates for the treatment of diseases like glaucoma, leukemia, epilepsy; Alzheimer's disease; type-2 diabetes mellitus that are associated with high enzymatic activity of Carbonic Anhydrase, acetylcholine esterase, butyrylcholinesterase, and α-glycosidase.

Keywords
Acetylcholinesterase; Butyrylcholinesterase; Carbonic anhydrase; Tris-chalcone; α-glycosidase.
Products